言語を選択

Catenin beta-1

Catenin beta-1 詳細

英語名	Catenin beta 1	市販薬剤の数	1
治験薬の数	10	ターゲットの別称	NEDSDV，OK/SW-cl.35，CTNNB1，PRO2286，Catenin Beta 1，Catenin (Cadherin-Associated Protein)， Beta 1， 88kDa，CTNNB，Catenin (Cadherin-Associated Protein)， Beta 1 (88kD)，Catenin (Cadherin-Associated Protein)， Beta 1，Catenin Beta-1，Beta-Catenin，Armadillo，MRD19，EVR7，beta Catenin，β-Catenin
研究＆開発段階	Approved

英語名	Catenin beta 1
ターゲットの別称	NEDSDV，OK/SW-cl.35，CTNNB1，PRO2286，Catenin Beta 1，Catenin (Cadherin-Associated Protein)， Beta 1， 88kDa，CTNNB，Catenin (Cadherin-Associated Protein)， Beta 1 (88kD)，Catenin (Cadherin-Associated Protein)， Beta 1，Catenin Beta-1，Beta-Catenin，Armadillo，MRD19，EVR7，beta Catenin，β-Catenin
市販薬剤の数	1
治験薬の数	10
研究＆開発段階	Approved

Catenin beta-1 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag (1)His Tag & Avi Tag (1)
マーカー
Unconjugated (1)Biotin-labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
CA1-H51H3	Human	E. coli	Human Catenin beta-1 Protein, His Tag (MALS verified)
CA1-H81E3	Human	E. coli	Biotinylated Human Catenin beta-1 Protein, His,Avitag™ (MALS verified)

総数量2

Catenin beta-1バックグランド

Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental cancer models of animals. The nuclear accumulation of β-catenin has been shown to be positively correlated with poor clinical outcomes, such as cancer progression, invasion, metastasis, and recurrence, resulting in low survival rates.

Catenin beta-1分子の別称

CTNNB, EVR7, MRD19, NEDSDV, armadillo

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
CEQ-508	CEQ-508	Phase 2 Clinical	Marina Biotech	Adenomatous Polyposis Coli	詳細
Foscenvivint	PRI-724; ICG-001; OP-724	Phase 2 Clinical	Prism Pharma Co Ltd, University Of Southern California	Colorectal Neoplasms; Hepatitis B; Hepatitis C; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Cirrhosis, Biliary; Pancreatic Neoplasms; Solid tumours	詳細
Tegatrabetan	BC-2059; APL-121	Phase 2 Clinical	Allergan Plc	Adenomatous Polyps; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Fibroma; Fibromatosis, Aggressive; Hepatoblastoma; Leukemia; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Neuroblastoma; Osteosarcoma; Pancreatic Neoplasms; Sarcoma, Ewing; Solid tumours; Wilms Tumor	詳細
Zolucatetide		Phase 2 Clinical	Parabilis Medicines Inc	Adenomatous Polyps	詳細
Urbagen gene addition therapy (CTNNB1 Foundation)		Phase 2 Clinical	CTNNB1 Foundation	Neurodevelopmental Disorders	詳細
Zolucatetide	FOG-001	Phase 2 Clinical	Parabilis Medicines Inc	Adenomatous Polyposis Coli; Carcinoma, Hepatocellular; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Fibromatosis, Aggressive; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours	詳細
E-7386	E-7386	Phase 2 Clinical	Eisai Co Ltd, Prism Pharma Co Ltd	Carcinoma, Hepatocellular; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Solid tumours	詳細
DPTX-3186	DPTX-3186; DPTX3186	Phase 1 Clinical	Dewpoint Therapeutics Inc	Solid tumours	詳細
ALN-BCAT	ALN-BCAT	Phase 1 Clinical	Alnylam Pharmaceuticals Inc	Carcinoma, Hepatocellular	詳細
ST-316	ST-316	Phase 1 Clinical	Sapience Therapeutics Inc	Colonic Neoplasms; Hematologic Neoplasms; Solid tumours	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Tetrandrine	NSC-77037; ES-3000; FF-0019	Approved	Escend Pharmaceuticals Inc		Mainland China	Silicosis; Lung Neoplasms	null	2015-05-19	Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Myelodysplastic Syndromes; Silicosis	詳細

レビュー

S***e2026-06-23
0評価
Biotinylated Human Catenin beta-1 Protein, His,Avitag™ (MALS verified)
It is working very well, but the packaging could be optimized a lot more (5 kg of dry ice for one tube seems a bit exaggerated).